PCSK9 and atherosclerosis: Our previous study showed that a nanoliposomal vaccine targeting PCSK9 could significantly induce the generation of antibodies inhibiting the plasma PCSK9 and thereby reducing the plasma LDL-C in an experimental model of atherosclerosis [37–40].